Disorders of phosphate metabolism in chronic renal disease.
Hyperphosphatemia directly or indirectly contributes to the progression of chronic renal disease and is an important factor in the development of secondary hyperparathyroidism and uremic bone disease. New therapeutic advances include the development of calcium-free intestinal phosphate binders, calcimimetics to control parathyroid hormone secretion and non-calcemic vitamin D analogs.
Edwards
Richard M
RM
Department of Renal and Urology Biology, UW2521, GlaxoSmithKline, PO Box 1539, King of Prussia, PA 19406-0939, USA. richard_m_edwards@gsk.com
D000818:Animals; D006801:Humans; D007676:Kidney Failure, Chronic / Q000178:diet therapy / Q000188:drug therapy / Q000378:metabolism* / Q000652:urine; D010710:Phosphates / Q000037:antagonists & inhibitors / Q000378:metabolism* / Q000652:urine; D014807:Vitamin D / Q000031:analogs & derivatives / Q000627:therapeutic use
D010710:Phosphates; D014807:Vitamin D